• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by CohBar Inc. (Amendment)

    2/8/23 9:00:30 AM ET
    $CWBR
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $CWBR alert in real time by email
    SC 13G/A 1 ea172597-13ga4barzil_cohbar.htm AMENDMENT NO. 4 TO SCHEDULE 13G
     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G
    (Amendment No. 4)*

     

    Under the Securities Exchange Act of 1934

     

    CohBar, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    19249J307

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)
    ☐Rule 13d-1(c)
    ☒Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 19249J307   SC 13G   Page 2 of 5

     

    1.  

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Nir Barzilai

    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)     ☐
    (b)     ☐
    3.  

    SEC USE ONLY

     
     

    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      5.   SOLE VOTING POWER
     
    172,839(1)
      6.   SHARED VOTING POWER
     
    0
      7.   SOLE DISPOSITIVE POWER
     
    172,839(1)
      8.  

    SHARED DISPOSITIVE POWER

     

    0

    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    172,839(1)
    10.  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)     ☐

     

    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.94%
    12.   TYPE OF REPORTING PERSON (see instructions)

    IN

     

    1.Includes an aggregate of 3,658 shares issuable upon exercise of stock options and warrants exercisable within 60 days of the date hereof.

     

     

     

     

    CUSIP No. 19249J307   SC 13G   Page 3 of 5

     

    Item 1.

     

      (a) Name of Issuer
    CohBar, Inc.
         
      (b)

    Address of Issuer’s Principal Executive Offices
    1455 Adams Drive

    Menlo Park, CA 94025

     

    Item 2.

     

      (a) Name of Person Filing
    Nir Barzilai
         
      (b)

    Address of the Principal Office or, if none, residence
    c/o CohBar, Inc.

    1455 Adams Drive

    Menlo Park, CA 94025

         
      (c) Citizenship
    United States of America
         
      (d) Title of Class of Securities
    Common Stock, par value $0.001 per share
         
      (e) CUSIP Number
    19249J307

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

     

     

    CUSIP No. 19249J307   SC 13G   Page 4 of 5

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned: 172,839*
           
      (b) Percent of class: 5.94%
           
      (c) Number of shares as to which the person has:
           
        (i) Sole power to vote or to direct the vote: 172,839*
           
        (ii) Shared power to vote or to direct the vote: 0
           
        (iii) Sole power to dispose or to direct the disposition of: 172,839*
           
        (iv) Shared power to dispose or to direct the disposition of: 0

     

    * Includes an aggregate of 3,658 shares issuable upon exercise of stock options and warrants exercisable within 60 days of the date hereof.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable

     

    Item 10. Certification.

     

    Not applicable

     

     

     

     

    CUSIP No. 19249J307   SC 13G   Page 5 of 5

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 8, 2023
      Date
       
      /s/ Nir Barzilai
      Signature
       
      Nir Barzilai
      Name

     

     

    Get the next $CWBR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CWBR

    DatePrice TargetRatingAnalyst
    8/11/2021$5.00Speculative Buy → Buy
    WBB Securities
    More analyst ratings

    $CWBR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Sarret Joseph J. was granted 131,017 shares, increasing direct ownership by 655% to 151,017 units

      4 - CohBar, Inc. (0001522602) (Issuer)

      8/3/22 9:00:22 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: Biunno Jeffrey Francis was granted 26,203 shares, increasing direct ownership by 84% to 57,355 units

      4 - CohBar, Inc. (0001522602) (Issuer)

      8/3/22 9:00:26 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Tozzo Stephanie

      4 - CohBar, Inc. (0001522602) (Issuer)

      7/12/22 4:06:36 PM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CWBR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)

      Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 20, 2023, CohBar, Inc. (the "Company") was notified by the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") of its determination pursuant to Nasdaq Listing Rule 5101 that, based upon the Staff's belief that the Company is a "public shell," and that the continued listing of the Company's securities is no longer warranted, and the Company's non-compliance with certain board and committee composition listing requirements under Nasdaq Listing Rule 5605 and certain of Nasdaq's filing requirements under Nasdaq Listing Rule 5250(c)(1)

      11/27/23 6:05:00 PM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar Reports Second Quarter 2023 Financial Results

      MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023. Second Quarter 2023 Summary and Financial Results Entered into Definitive Merger Agreement with Morphogenesis: In May 2023, CohBar announced that the company entered into a definitive merger agreement with a privately held biotechnology company, Morphogenesis, Inc. ("Morphogenesis"), for an all-stock transaction to advance a late-stage oncology pipeline. The combined company is expected to operate under the name "TuHURA Biosciences, Inc." and to trade on The Nasdaq Capital Market ("Nasdaq"). The transaction is exp

      8/14/23 4:01:05 PM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

      IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5 of 7 (71%) of patients achieved durable systemic anti-tumor responses following IFx-Hu2.0 therapy and rechallenge with an immune checkpoint inhibitor (ICI) in patients who exhibited primary resistance to ICIs Translational biomarker data underscores IFx-Hu2.0 mechanism; Demonstrates activation of systemic tumor-specific immune responses Data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting TAMPA, Fa. and MENLO PARK, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. ("Morphogenesis"), a privately-held Phase 2/3 clinical-stage biotechnology compa

      6/5/23 8:05:22 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CWBR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CWBR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form SC 13G/A filed by CohBar Inc. (Amendment)

      SC 13G/A - CohBar, Inc. (0001522602) (Subject)

      2/8/23 9:00:30 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by CohBar Inc. (Amendment)

      SC 13G/A - CohBar, Inc. (0001522602) (Subject)

      2/8/23 9:00:30 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by CohBar Inc. (Amendment)

      SC 13G/A - CohBar, Inc. (0001522602) (Subject)

      2/14/22 3:31:32 PM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar upgraded by WBB Securities with a new price target

      WBB Securities upgraded CohBar from Speculative Buy to Buy and set a new price target of $5.00

      8/11/21 7:20:55 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Maxim Group initiated coverage on CohBar with a new price target

      Maxim Group initiated coverage of CohBar with a rating of Buy and set a new price target of $3.00

      4/23/21 9:00:48 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aegis Capital initiated coverage on CohBar with a new price target

      Aegis Capital initiated coverage of CohBar with a rating of Buy and set a new price target of $6.00

      3/15/21 11:37:59 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CWBR
    Leadership Updates

    Live Leadership Updates

    See more
    • CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors

      MENLO PARK, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced the appointment of Effie Tozzo, Ph.D. as an independent director on the company's Board, effective July 11, 2022. Dr. Tozzo brings extensive research and development experience at both established pharmaceutical and innovative biotechnology companies. "We are delighted to add Dr. Tozzo to our Board and will tap into her considerable expertise in advancing preclinical assets to the clini

      7/12/22 9:00:00 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar Announces Changes to its Board of Directors and R&D Leadership

      Founding board members transition to reconstituted Scientific Advisory Board Kent Grindstaff, Ph.D. appointed as Senior Vice President of Research MENLO PARK, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced changes to its Board of Directors, Scientific Advisory Board (SAB), and R&D leadership. CohBar's founders Drs. Nir Barzilai, Pinchas Cohen, and John Amatruda have transitioned from the company's Board of Directors to a reconstituted SAB. The SAB will be comprised of experts in mitochondrial science and other dis

      12/17/21 9:00:00 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors

      MENLO PARK, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Joanne Yun, Ph.D. as an independent director on the company's Board, effective September 14, 2021. Dr. Yun brings extensive research and development, commercial, and governance experience from the pharmaceutical industry. "We are very pleased to add Dr. Yun as an independent director and look forward to her strategic input as we continue to develop our diverse pipeline of novel mitochondria based therapeutics," said David Greenwood, Chair

      9/15/21 9:00:00 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CWBR
    Financials

    Live finance-specific insights

    See more

    $CWBR
    SEC Filings

    See more
    • Lifshitz Law PLLC Announces Investigations of CWBR, GHL, PDCE, and VECT

      NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CWBR and Morphogenesis, Inc. Under the terms of the proposed merger, CWBR shareholders will receive a dividend equal to approximately 3.30 shares of CWBR common stock. Following the merger, pre-merger CohBar shareholders are expected to own approximately 15% of the outstanding equity of the combined company. If you are a CWBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-

      6/3/23 8:17:00 PM ET
      $CWBR
      $GHL
      $PDCE
      $VECT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Investment Bankers/Brokers/Service
      Finance
    • CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

      Combined company will operate under the name "TuHURA Biosciences, Inc." and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulatorsLead asset, IFx-Hu2.0, expected to enter Phase 2/3 registration trial as first-line treatment for Merkel Cell Carcinoma in early 2024$15 million PIPE financing to close concurrent with the closing of the proposed merger – combined company expected to have cash runway through 2024Companies to hold a joint conference call and webcast today, Tuesday, May 23rd at 8:30 AM ET MENLO PARK, Calif. and TAMPA, Fla. , May 23, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) ("CohBar" or the "company") and Morphogenesis, Inc. ("M

      5/23/23 7:30:39 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

      MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress. "I'm pleased with the team's performance during the third quarter of 2022 in advancing our top priorities, including improving the formulation of CB5138-3, our product candidate for IPF," stated Dr. Joseph Sarret, Chief Executive Officer. "We continue to operate the company i

      11/8/22 4:03:07 PM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 25-NSE filed by CohBar Inc.

      25-NSE - CohBar, Inc. (0001522602) (Subject)

      12/27/23 9:01:40 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - CohBar, Inc. (0001522602) (Filer)

      11/27/23 5:21:26 PM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar Inc. filed SEC Form 8-K: Leadership Update, Other Events

      8-K - CohBar, Inc. (0001522602) (Filer)

      11/13/23 9:01:36 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care